Short Interest in HCW Biologics Inc. (NASDAQ:HCWB) Grows By 1,686.4%

HCW Biologics Inc. (NASDAQ:HCWB) was the target of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 144,700 shares, a growth of 1,686.4% from the October 31st total of 8,100 shares. Approximately 0.7% of the shares of the company are sold short. Based on an average daily volume of 8,960,000 shares, the days-to-cover ratio is currently 0.0 days.

HCW Biologics Stock Performance

Shares of HCWB stock traded down $0.04 during midday trading on Wednesday, hitting $0.51. 588,926 shares of the company were exchanged, compared to its average volume of 2,578,727. The firm has a market capitalization of $19.42 million, a P/E ratio of -0.54 and a beta of 0.83. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.07 and a current ratio of 0.07. HCW Biologics has a 52 week low of $0.28 and a 52 week high of $2.52. The firm’s 50 day moving average price is $0.53 and its two-hundred day moving average price is $0.67.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.